Mefruside
Based on 1 Customer Validation
Mefruside is an orally active diuretic and has a mild hypotensive effect. Mefruside inhibits the synthesis of urea in an isolated rat liver perfusion model. Mefruside can be used in studies of oedema and hypertension.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.9%
- CAS. Nr.: 7195-27-9
- Formel: C13H19ClN2O5S2
- Molecular Weight:382.88
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Beschreibung
In Vitro
Mefruside (0.3 mM; 50 min) shows 34% inhibition of urea synthesis in isolated perfused rat liver[1].
Mefruside (0.25, 0.5, 0.75, 1, 1.25 mM) inhibits urea synthesis in a concentration-dependent manner in isolated perfused rat liver[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Rat liver (from male Wistar rats of 120-220 g body weight; isolated perfused model)
-
Concentration:0.3 mM
-
Incubation Time:50 min
-
Result:Exhibited inhibition rate of urea synthesis of 34%.
Chemical Information
-
CAS. Nr. 7195-27-9
-
Appearance Solid
-
Molecular Weight 382.88
-
Formel C13H19ClN2O5S2
-
Color White to off-white
-
SMILES
O=S(C1=CC=C(C(S(=O)(N)=O)=C1)Cl)(N(CC2(OCCC2)C)C)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Reinheit & Dokumentation
-
Data Sheet (269 KB)
-
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Korean - KR (557 KB)
- Portuguese - PT (557 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Häussinger D, et al. Liver carbonic anhydrase and urea synthesis. Hepatology. 1988 Mar-Apr;8(2):435. [Content Brief]
[2]. Brogden RN, et al. Mefruside: a preliminary report of its pharmacological properties and therapeutic efficacy in oedema and hypertension. Drugs. 1974;7(6):419-25. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Mefruside Related Classifications
HY-123179 Related Classifications
Powered by Bioz